Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias. The investigators aim to study: 1. the prevalence and mechanism of inducible ventricular tachycardia 2. pace-mapping to define the site of origin of ventricular arrhythmias 3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy. Participants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.

Who May Be Eligible (Plain English)

Who May Qualify: - Adults aged 18 and older - Diagnosed with AF, frequent PVCs, or VT before age 60 - Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation - Able to provide written, willing to sign a consent form - P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control. Who Should NOT Join This Trial: - Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure - VUS in 'possibly pathogenic' subgroup (control group only) - Previous PVC or VT ablation - LVEF \<20% - Prosthetic mitral or aortic valve - Contraindication to heparin - Prior myocardial infarction Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adults aged 18 and older * Diagnosed with AF, frequent PVCs, or VT before age 60 * Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation * Able to provide written, informed consent * P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control. Exclusion Criteria: * Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure * VUS in 'possibly pathogenic' subgroup (control group only) * Previous PVC or VT ablation * LVEF \<20% * Prosthetic mitral or aortic valve * Contraindication to heparin * Prior myocardial infarction

Locations (1)

Vanderbilt University Medical Center
Nashville, Tennessee, United States